MCID: ATS007
MIFTS: 65

Autism Spectrum Disorder

Categories: Rare diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Autism Spectrum Disorder

MalaCards integrated aliases for Autism Spectrum Disorder:

Name: Autism Spectrum Disorder 12 50 25 51 41 14
Autism Spectrum Disorders 24 29 69
Asd 50 25
Pervasive Developmental Disorder 25
Pervasive Development Disorder 69
Autistic Continuum 25
Autistic Behavior 69
Pdds 24

Classifications:



External Ids:

Disease Ontology 12 DOID:0060041

Summaries for Autism Spectrum Disorder

MedlinePlus : 41 autism spectrum disorder (asd) is a neurological and developmental disorder that begins early in childhood and lasts throughout a person's life. it affects how a person acts and interacts with others, communicates, and learns. it includes what used to be known as asperger syndrome and pervasive developmental disorders. it is called a "spectrum" disorder because people with asd can have a range of symptoms. people with asd might have problems talking with you, or they might not look you in the eye when you talk to them. they may also have restricted interests and repetitive behaviors. they may spend a lot of time putting things in order, or they may say the same sentence again and again. they may often seem to be in their "own world." at well-child checkups, the health care provider should check your child's development. if there are signs of asd, your child will have a comprehensive evaluation. it may include a team of specialists, doing various tests and evaluations to make a diagnosis. the causes of asd are not known. research suggests that both genes and environment play important roles. there is currently no one standard treatment for asd. there are many ways to increase your child's ability to grow and learn new skills. starting them early can lead to better results. treatments include behavior and communication therapies, skills training, and medicines to control symptoms. nih: national institute of child health and human development

MalaCards based summary : Autism Spectrum Disorder, also known as autism spectrum disorders, is related to atypical autism and adnp-related intellectual disability and autism spectrum disorder, and has symptoms including fatigue, sleep disturbances and photophobia. An important gene associated with Autism Spectrum Disorder is EHMT1 (Euchromatic Histone Lysine Methyltransferase 1), and among its related pathways/superpathways are Transmission across Chemical Synapses and Neuroscience. The drugs Aripiprazole and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and eye, and related phenotypes are behavior/neurological and nervous system

NIH Rare Diseases : 50 autism spectrum disorder (asd) is a condition that affects the development of social and communication skills. it includes features of four conditions which were once thought to be separate syndromes - autistic disorder, asperger syndrome, childhood disintegrative disorder, and pervasive developmental disorder. signs and symptoms often become apparent in the first 2-3 years of life and vary significantly from person to person. common symptoms shared by people with asd include restrictive and repetitive behaviors, social impairment and communication difficulties. the underlying cause of asd is generally unknown and it is likely that a variety of factors contribute to the development of the condition. asd appears to run in some families, suggesting that genetics may play a role in some cases. although there is no cure for asd, treatment is available that significantly improves the long-term outlook for affected people. treatment often includes a combination of techniques such as medications, occupational therapy, speech therapy and physical therapy. last updated: 12/1/2016

NINDS : 51 Autistic disorder (sometimes called autism or classical ASD) is the most common condition in a group of developmental disorders known as the autism spectrum disorders (ASDs). Autistic children have difficulties with social interaction, display problems with verbal and nonverbal communication, and exhibit repetitive behaviors or narrow, obsessive interests. These behaviors can range in impact from mild to disabling. Autism varies widely in its severity and symptoms and may go unrecognized, especially in mildly affected children or when more debilitating handicaps mask it. Scientists aren’t certain what causes autism, but it’s likely that both genetics and environment play a role.

Genetics Home Reference : 25 Autism spectrum disorder (ASD) is a condition that appears very early in childhood development, varies in severity, and is characterized by impaired social skills, communication problems, and repetitive behaviors. These difficulties can interfere with affected individuals' ability to function in social, academic, and employment settings. People with ASD also have an increased risk of psychiatric problems such as anxiety, depression, obsessive-compulsive disorder, and eating disorders.

Disease Ontology : 12 A pervasive developmental disorder that is a spectrum of psychological conditions. The disease has symptom widespread abnormalities of social interactions and communication, has symptom severely restricted interests and has symptom highly repetitive behavior.

Wikipedia : 72 Autism spectrum, also known as autism spectrum disorder (ASD), describes a range of conditions... more...

Related Diseases for Autism Spectrum Disorder

Diseases in the Autism Spectrum Disorder family:

Autism 19 Autism 9
Autism 10 Autism 18

Diseases related to Autism Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 166, show less)
id Related Disease Score Top Affiliating Genes
1 atypical autism 32.4 CHD8 CNTNAP2 MECP2 NLGN3 NLGN4X RPL10
2 adnp-related intellectual disability and autism spectrum disorder 12.2
3 autism spectrum disorder susceptibility, chd8-related 12.0
4 autism spectrum disorder susceptibility, kmt5b-related 12.0
5 intellectual disability and/or autism spectrum disorder, ash1l-related 12.0
6 patent foramen ovale 11.8
7 adnp syndrome 11.7
8 helsmoortel-van der aa syndrome 11.5
9 arthrogryposis, mental retardation, and seizures 11.5
10 asperger syndrome 11.5
11 fragile x syndrome 11.2
12 specific language impairment 11.1
13 rett syndrome 11.1
14 pervasive developmental disorder 11.1
15 chromosome 15q13.3 microdeletion syndrome 11.1
16 16p11.2 duplication 11.1
17 mental retardation, autosomal dominant 26 11.0
18 mental retardation, autosomal recessive 38 11.0
19 epilepsy, familial focal, with variable foci 1 10.9
20 timothy syndrome 10.9
21 autism x-linked 4 10.9
22 neurodevelopmental disorder with or without anomalies of the brain, eye, or heart 10.9
23 chromosome 15q11.2 deletion syndrome 10.9
24 specific language impairment 5 10.9
25 schaaf-yang syndrome 10.9
26 childhood disintegrative disease 10.9
27 syngap1-related intellectual disability 10.9
28 iris hypoplasia 10.8 CNTNAP2 MECP2 SETD2 SHANK3
29 familial partial lipodystrophy 10.8 NLGN3 NLGN4X SHANK3
30 brachycephaly, trichomegaly, and developmental delay 10.8
31 autism susceptibility 17 10.8
32 47,xyy syndrome 10.8
33 hivep2-related intellectual disability 10.8
34 chromosome 1q21.1 deletion syndrome 10.8
35 speech and communication disorders 10.8
36 syngap1-related non-syndromic intellectual disability 10.8
37 athabaskan brainstem dysgenesis syndrome 10.8
38 autism susceptibility, x-linked 2 10.8
39 autistic disorder 10.8
40 cask-related disorders 10.8
41 autism 18 10.8
42 autism susceptibility, x-linked 1 10.8
43 16p11.2 deletion syndrome 10.8
44 autism 9 10.8
45 17q12 deletion syndrome 10.8
46 autism susceptibility 15 10.8
47 autism susceptibility, x-linked 3 10.8
48 pervasive developmental disorder not otherwise specified 10.8
49 autism 10 10.8
50 autism x-linked 5 10.8
51 autosomal dominant intellectual disability 30 10.8
52 ppp2r5d-related intellectual disability 10.8
53 chromosome 2q37 deletion syndrome 10.8
54 autism x-linked 6 10.8
55 epilepsy, familial focal, with variable foci 2 10.8
56 macrocephaly/autism syndrome 10.8
57 chromosome 16p13.3 duplication syndrome 10.8
58 luscan-lumish syndrome 10.8
59 epilepsy, familial focal, with variable foci 3 10.8
60 autism susceptibility 16 10.8
61 potocki-lupski syndrome 10.8
62 chromosome 3p- syndrome 10.8
63 hyperglycemia 10.8 CNTNAP2 SHANK3
64 paraphilia disorder 10.5 NLGN3 NLGN4X
65 attention deficit-hyperactivity disorder 10.4
66 intellectual disability 10.4
67 schizophrenia 10.3
68 autoimmune-related retinopathy and optic neuropathy 10.3 CNTNAP2 HOXA1 MECP2 NLGN3 NLGN4X SCN2A
69 epilepsy 10.2
70 cerebritis 10.1
71 down syndrome 10.1
72 prader-willi syndrome 10.1
73 developmental coordination disorder 10.0
74 cerebral palsy 10.0
75 fetal alcohol spectrum disorder 10.0
76 neuronitis 10.0
77 tuberous sclerosis 10.0
78 neurofibromatosis, type 1 9.9
79 dyslexia 9.9
80 conduct disorder 9.9
81 learning disability 9.9
82 phelan-mcdermid syndrome 9.9
83 obsessive-compulsive disorder 9.9
84 bipolar disorder 9.9
85 cornelia de lange syndrome 9.9
86 rubella 9.9
87 childhood-onset schizophrenia 9.9
88 bipolar i disorder 9.8
89 hyperprolactinemia 9.8
90 smith-lemli-opitz syndrome 9.8
91 ileocolitis 9.8
92 megalencephaly 9.8
93 jacobsen syndrome 9.8
94 pilocytic astrocytoma 9.8
95 hyperacusis 9.8
96 mumps 9.8
97 borna disease 9.8
98 endotheliitis 9.8
99 infertility 9.8
100 sleep disorder 9.8
101 williams-beuren syndrome 9.8
102 brain injury 9.8
103 tic disorder 9.8
104 gender identity disorder 9.8
105 astrocytoma 9.8
106 oppositional defiant disorder 9.8
107 measles 9.8
108 eating disorder 9.8
109 chiari malformation 9.8
110 autonomic dysfunction 9.8
111 alexithymia 9.8
112 anorexia nervosa 9.8
113 apraxia 9.8
114 optic nerve hypoplasia 9.6
115 body dysmorphic disorder 9.6
116 placental insufficiency 9.6
117 muscular dystrophy 9.6
118 congenital cytomegalovirus 9.6
119 dysautonomia 9.6
120 duchenne muscular dystrophy 9.6
121 leopard syndrome 9.6
122 echolalia 9.6
123 congenital rubella 9.6
124 cri-du-chat syndrome 9.6
125 seizure disorder 9.6
126 adenomatous polyposis coli 9.6
127 femoral-facial syndrome 9.6
128 anxiety disorder 9.6
129 7q11.23 duplication syndrome 9.6
130 spasticity 9.6
131 succinic semialdehyde dehydrogenase deficiency 9.6
132 constipation 9.6
133 microphthalmia 9.6
134 neonatal jaundice 9.6
135 tetrasomy 9p 9.6
136 early-onset schizophrenia 9.6
137 trichotillomania 9.6
138 separation anxiety disorder 9.6
139 psychotic disorder 9.6
140 mitochondrial disorders 9.6
141 distal trisomy 10q 9.6
142 corneal dystrophy 9.6
143 strabismus 9.6
144 charge syndrome 9.6
145 lyme disease 9.6
146 juvenile pilocytic astrocytoma 9.6
147 angelman syndrome 9.6
148 paranoid schizophrenia 9.6
149 antiphospholipid syndrome 9.6
150 axonal neuropathy 9.6
151 cerebrotendinous xanthomatosis 9.6
152 gingivitis 9.6
153 nicolaides-baraitser syndrome 9.6
154 mood disorder 9.6
155 cerebral folate deficiency 9.6
156 drug addiction 9.6
157 xanthomatosis 9.6
158 neuropathy 9.6
159 costello syndrome 9.6
160 piebaldism 9.6
161 cytomegalovirus infection 9.6
162 scurvy 9.6
163 amenorrhea 9.6
164 superior mesenteric artery syndrome 9.6
165 developmental dyspraxia 9.6
166 sexual disorder 9.4 ADNP CHD8 CNTNAP2 EHMT1 HOXA1 MECP2

Graphical network of the top 20 diseases related to Autism Spectrum Disorder:



Diseases related to Autism Spectrum Disorder

Symptoms & Phenotypes for Autism Spectrum Disorder

UMLS symptoms related to Autism Spectrum Disorder:


fatigue, sleep disturbances, photophobia, personality changes, restlessness, pseudobulbar behavioral symptoms

MGI Mouse Phenotypes related to Autism Spectrum Disorder:

44 (showing 2, show less)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.65 SHANK1 SHANK2 SHANK3 SNRPN CNTNAP2 EHMT1
2 nervous system MP:0003631 9.36 ADNP CNTNAP2 EHMT1 HOXA1 MECP2 NLGN3

Drugs & Therapeutics for Autism Spectrum Disorder

Drugs for Autism Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 283, show less)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aripiprazole Approved, Investigational Phase 4,Phase 3,Phase 2 129722-12-9 60795
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3 113-45-1 4158
4
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
5
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 19982-08-2 4054
6
Guanfacine Approved, Investigational Phase 4 29110-47-2 3519
7
Milnacipran Approved Phase 4 92623-85-3 65833
8
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
9
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
10
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 106266-06-2 5073
11
Ziprasidone Approved Phase 4,Phase 3,Phase 2 146939-27-7 60854
12
Donepezil Approved Phase 4,Phase 1,Phase 2 120014-06-4 3152
13
Acetylcysteine Approved, Investigational Phase 4,Phase 2 616-91-1 12035
14
Acetylcholine Approved Phase 4,Phase 1 51-84-3 187
15
Melatonin Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 73-31-4 896
16
Choline Approved, Nutraceutical Phase 4 62-49-7 305
17 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Phase 1
18 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1
19 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Phase 1
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Antibodies Phase 4
23 gamma-Globulins Phase 4
24 Immunoglobulins Phase 4
25 Immunoglobulins, Intravenous Phase 4
26 Rho(D) Immune Globulin Phase 4
27 Antiparkinson Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
28 Dopamine Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Excitatory Amino Acid Antagonists Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
30 Excitatory Amino Acids Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
31 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
32 Adrenergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
33 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
34 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Phase 1
35 Dopamine Uptake Inhibitors Phase 4,Phase 3,Phase 2
36 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
37 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1
38 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
39 Antiviral Agents Phase 4,Phase 2
40 Respiratory System Agents Phase 4,Phase 2,Phase 3
41 Oxytocics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Atomoxetine Hydrochloride Phase 4,Phase 3
43 Adrenergic Agonists Phase 4,Phase 2
44 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2
45 Adrenergic alpha-Agonists Phase 4,Phase 2
46 Antihypertensive Agents Phase 4,Phase 2,Phase 1,Early Phase 1
47 Antidepressive Agents Phase 4,Phase 3,Phase 2,Phase 1
48
Serotonin Phase 4,Phase 3,Phase 2,Phase 1 50-67-9 5202
49 Serotonin Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Serotonin Uptake Inhibitors Phase 4,Phase 2,Phase 1
51 Hypoglycemic Agents Phase 4,Phase 3,Phase 2
52 Antiemetics Phase 4,Phase 2
53 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
54 Dopamine Antagonists Phase 4,Phase 3,Phase 2,Phase 1
55 Gastrointestinal Agents Phase 4,Phase 3,Phase 1,Phase 2
56 insulin Phase 4,Phase 2
57 Insulin, Globin Zinc Phase 4,Phase 2
58 Serotonin Antagonists Phase 4,Phase 3,Phase 2,Phase 1
59 Antimetabolites Phase 4,Phase 3
60 Cholinesterase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
61 Nootropic Agents Phase 4,Phase 3,Phase 1,Phase 2
62 Vasodilator Agents Phase 4,Early Phase 1
63 Antidotes Phase 4,Phase 3,Phase 2
64 Antioxidants Phase 4,Phase 2,Phase 3,Phase 1
65 Expectorants Phase 4,Phase 2
66 N-monoacetylcystine Phase 4,Phase 2
67 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
68 Hypolipidemic Agents Phase 4
69 Lipid Regulating Agents Phase 4
70 Omega 3 Fatty Acid Nutraceutical Phase 4,Phase 2
71 cysteine Nutraceutical Phase 4,Phase 2
72
Adenosine Approved, Investigational Phase 2, Phase 3 58-61-7 60961
73
Dextromethorphan Approved Phase 2, Phase 3 125-71-3 5360696 5362449
74
Guaifenesin Approved, Vet_approved Phase 2, Phase 3 93-14-1 3516
75
Benzocaine Approved Phase 2, Phase 3,Phase 1 1994-09-7, 94-09-7 2337
76
Riluzole Approved, Investigational Phase 2, Phase 3 1744-22-5 5070
77
Diphenhydramine Approved Phase 2, Phase 3 58-73-1, 147-24-0 3100
78
Fluoxetine Approved, Vet_approved Phase 2, Phase 3 54910-89-3 3386
79
Promethazine Approved Phase 2, Phase 3 60-87-7 4927
80
Cycloserine Approved Phase 3 68-41-7 401 6234
81
Acamprosate Approved, Investigational Phase 3,Phase 2 77337-76-9 71158
82
Ethanol Approved Phase 3,Phase 2 64-17-5 702
83
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
84
Hydroxocobalamin Approved Phase 2, Phase 3 13422-51-0 11953898 5460373 44475014
85
Galantamine Approved Phase 3 357-70-0 9651
86
Secretin Approved, Investigational Phase 3 108153-74-8
87
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
88
Bisacodyl Approved Phase 3 603-50-9
89
Glycerol Approved, Investigational Phase 3,Early Phase 1 56-81-5 753
90
Metronidazole Approved Phase 2, Phase 3 443-48-1 4173
91
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
92
Mianserin Approved Phase 3 24219-97-4 4184
93
Mirtazapine Approved Phase 3 85650-52-8, 61337-67-5 4205
94 tannic acid Approved, Nutraceutical Phase 2, Phase 3,Phase 1
95
Ergocalciferol Approved, Nutraceutical Phase 2, Phase 3 50-14-6 5280793
96
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2, Phase 3 1406-16-2
97
Cyanocobalamin Approved, Nutraceutical Phase 2, Phase 3 68-19-9 44176380
98
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2, Phase 3, Phase 1 59-30-3 6037
99
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
100 Hormone Antagonists Phase 3,Phase 2
101 Hormones Phase 3,Phase 2
102 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
103 Adrenergic alpha-Antagonists Phase 3,Phase 2,Phase 1
104 Adrenergic Antagonists Phase 3,Phase 2,Phase 1,Early Phase 1
105 Antiparasitic Agents Phase 2, Phase 3,Phase 1
106 Antiprotozoal Agents Phase 2, Phase 3,Phase 1
107 Antitussive Agents Phase 2, Phase 3
108 Chlorpheniramine, phenylpropanolamine drug combination Phase 2, Phase 3
109 Anticonvulsants Phase 2, Phase 3
110 Neuroprotective Agents Phase 2, Phase 3
111 Adrenergic beta-Antagonists Phase 2, Phase 3,Early Phase 1
112 Lithium carbonate Phase 2, Phase 3 554-13-2
113 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
114 Antibiotics, Antitubercular Phase 3,Phase 1,Phase 2
115 Antitubercular Agents Phase 3
116 Renal Agents Phase 3
117 triamcinolone acetonide Phase 3
118 Triamcinolone diacetate Phase 3
119 Triamcinolone hexacetonide Phase 3
120 Fluorodeoxyglucose F18 Phase 3
121 Bone Density Conservation Agents Phase 2, Phase 3
122 Ergocalciferols Phase 2, Phase 3
123 Micronutrients Phase 2, Phase 3, Phase 1, Early Phase 1
124 Trace Elements Phase 2, Phase 3, Phase 1, Early Phase 1
125 Vitamins Phase 2, Phase 3, Phase 1
126 Vitamin B 12 Phase 2, Phase 3
127 Vitamin B Complex Phase 2, Phase 3, Phase 1
128 Dopamine D2 Receptor Antagonists Phase 3,Phase 2,Phase 1
129 Paliperidone Palmitate Phase 3
130 Serotonin 5-HT2 Receptor Antagonists Phase 3,Phase 2,Phase 1
131
Lurasidone hydrochloride Phase 3,Phase 2,Phase 1 367514-87-2 213046
132 Antidepressive Agents, Second-Generation Phase 3,Phase 2,Phase 1
133 Hematinics Phase 3,Phase 2
134 Antidepressive Agents, Tricyclic Phase 3
135 Histamine Antagonists Phase 3
136 Histamine H1 Antagonists Phase 3
137
Histamine Phosphate Phase 3 51-74-1 65513
138 Epoetin alfa Phase 3 113427-24-0
139 Calciferol Nutraceutical Phase 2, Phase 3
140 Vitamin D2 Nutraceutical Phase 2, Phase 3
141
Cobalamin Nutraceutical Phase 2, Phase 3 13408-78-1 6438156
142 Folate Nutraceutical Phase 2, Phase 3, Phase 1
143
Methylcobalamin Experimental, Nutraceutical Phase 2, Phase 3 13422-55-4
144 Vitamin B12 Nutraceutical Phase 2, Phase 3
145 Vitamin B9 Nutraceutical Phase 2, Phase 3, Phase 1
146
Naltrexone Approved, Investigational, Vet_approved Phase 1, Phase 2 16590-41-3 5360515
147
Quinidine Approved Phase 2 56-54-2 441074
148
Amantadine Approved Phase 2 768-94-5 2130
149
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
150
Iron Approved Phase 2 7439-89-6 23925
151
Baclofen Approved Phase 2,Phase 1 1134-47-0 2284
152
Pioglitazone Approved, Investigational Phase 2 111025-46-8 4829
153
Suramin Approved Phase 1, Phase 2 145-63-1 5361
154
Lenalidomide Approved Phase 2 191732-72-6 216326
155
Omeprazole Approved, Investigational, Vet_approved Phase 1, Phase 2 73590-58-6 4594
156
Vancomycin Approved Phase 1, Phase 2 1404-90-6 441141 14969
157
Citalopram Approved Phase 2,Phase 1 59729-33-8 2771
158
Magnesium Sulfate Approved, Vet_approved Phase 2 7487-88-9 24083
159
Zinc Approved Phase 2,Phase 1 7440-66-6 32051 23994
160
Everolimus Approved Phase 2 159351-69-6 6442177
161
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
162
Sertraline Approved Phase 2 79617-96-2 68617
163
Coal tar Approved Phase 2 8007-45-2
164
Dronabinol Approved, Illicit Phase 2 1972-08-3 16078 2978
165
Buspirone Approved, Investigational Phase 2 36505-84-7 2477
166
Bumetanide Approved Phase 2 28395-03-1 2471
167
Amphetamine Approved, Illicit Phase 2 300-62-9 5826 3007
168 Orange Approved, Nutraceutical Phase 2
169
Glutamic Acid Approved, Nutraceutical Phase 2,Early Phase 1 56-86-0 33032
170
B-Carotene Approved, Nutraceutical Phase 2 7235-40-7 5280489
171
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 11103-57-4, 68-26-8 445354
172 Narcotic Antagonists Phase 1, Phase 2
173 Narcotics Phase 1, Phase 2
174 Anti-Arrhythmia Agents Phase 2,Early Phase 1
175 Antimalarials Phase 2
176 Cholinergic Antagonists Phase 2,Phase 1
177 Cytochrome P-450 CYP2D6 Inhibitors Phase 2
178 Cytochrome P-450 Enzyme Inhibitors Phase 2
179 Diuretics, Potassium Sparing Phase 2
180 Muscarinic Antagonists Phase 2,Phase 1
181 Quinidine gluconate Phase 2
182 Sodium Channel Blockers Phase 2
183 Analgesics Phase 2,Phase 1
184 Analgesics, Non-Narcotic Phase 2
185 Antifungal Agents Phase 2
186 Anti-Inflammatory Agents Phase 2
187 Caseins Phase 2
188 Chelating Agents Phase 2
189 Anthelmintics Phase 1, Phase 2
190 Angiogenesis Inhibitors Phase 2
191 Angiogenesis Modulating Agents Phase 2
192 Immunosuppressive Agents Phase 2
193 Antacids Phase 1, Phase 2
194 Anti-Ulcer Agents Phase 1, Phase 2
195
Proton pump inhibitors Phase 1, Phase 2
196 Parasympatholytics Phase 2,Phase 1
197 Anesthetics Phase 2,Phase 1